Bone Biologics Corporation (BBLG) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -804.28K | -714.76K | -591.38K | -458.88K | -926.13K | -1.35M | -572.16K | -895.87K | -1.3M | -2.02M | -2.56M | -3.63M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 13.16% | 47.19% | -3.36% | 48.78% | 28.95% | 32.93% | 77.61% | 75.34% | 3.45% | -3.45% | -546.44% | -908.9% |
| Net Income | -765.99K | -684.64K | -666.74K | -740.52K | -1.02M | -1.52M | -941K | -783.73K | -865.97K | -1.55M | -1.92M | -1.77M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 45.67K | 0 | 72.9K | 50.6K | 100.75K | 17.94K | 17.44K | 52.68K | 71.14K | 20.03K | 16.67K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 23.24K | -498 | 15.32K | -902 | -1.35K | -12.96K | 9.97K | -10.79K | -37.31K | -24.76K | -160.65K | -1.27M |
| Working Capital Changes | -61.53K | -75.3K | 60.03K | 209.64K | 41.72K | 80.42K | 340.93K | -118.79K | -452.81K | -514.51K | -494.89K | -609.9K |
| Change in Receivables | 2.09K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -74.08K | 84.8K | 0 | 155.89K | -79.02K | 182.99K | -41.81K | 85.69K | -137.08K | 41.62K | -586.37K | -590.1K |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 0 | 0 | 0 | 4.35M | 347.55K | 1.11M | 1.81M | 299 | 1.5M | 592K | 0 | 4.45M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 4.35M | 347.55K | 1.11M | -226 | -137 | 1.5M | 592K | 0 | 4.45M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | -3.21M | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 0 | 5.02M | 436 | 0 | 0 | 0 | 0 |
| Net Change in Cash | -804.28K | -714.76K | -591.38K | 3.89M | -578.58K | -241.29K | 1.23M | -895.57K | 201.06K | -1.43M | -2.56M | 819.49K |
| Free Cash Flow | -804.28K | -714.76K | -591.38K | -458.88K | -926.12K | -1.35M | -572.16K | -895.87K | -1.3M | -2.02M | -2.56M | -3.63M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 13.16% | 47.19% | -3.36% | 48.78% | 28.95% | 32.93% | 77.61% | 75.34% | 3.45% | -3.45% | -546.44% | -908.9% |
| FCF per Share | -0.45 | -0.61 | -0.33 | -0.82 | -0.29 | -0.46 | -0.33 | -0.77 | -1.97 | -4.40 | -6.52 | -10.71 |
| FCF Conversion (FCF/Net Income) | 1.05x | 1.04x | 0.89x | 0.62x | 0.91x | 0.89x | 0.61x | 1.14x | 1.51x | 1.30x | 1.33x | 2.05x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |